Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 08, 2016 07:32 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Reports Fiscal Year 2015 Financial Results and Provides Corporate Update

Net Income of $58 Million Generated mainly due to the Sale of Our Share in Collaboration to Pfizer Strong Cash Position of $76.3 Million Projected to Fund Operations into 2018 Special...
March 03, 2016 07:00 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Presents Positive Six and Twelve Month Interim Clinical Data on PRX-102 for the Treatment of Fabry Disease at the 12th Annual WORLDSymposium™ 2016

Demonstrated Effectiveness Across All Disease Parameters Including Cardiac and Kidney FunctionsPRX-102 Safe and Well Tolerated With Very Low Formation of AntibodiesCARMIEL, Israel, March 03, 2016 ...
February 22, 2016 07:30 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics to Participate in the SunTrust Robinson Humphrey Orphan Drug Day and the 12th Annual WORLDSymposium™ 2016

CARMIEL, Israel, Feb. 22, 2016 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE:PLX) and (TASE:PLX), announced today that the Company will participate in the SunTrust Robinson Humphrey...
November 16, 2015 07:00 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics to Conduct Phase III Clinical Trial for PRX-102 for the Treatment of Fabry Disease Following a Successful End-of-Phase II Meeting With FDA

Clear Path for Biologics License Application (BLA) Submission One Short-Term Safety and Efficacy Study Required to Support Full Approval In Parallel, Protalix to Conduct Phase III Head-to-Head...
November 09, 2015 16:05 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Reports Third Quarter 2015 Financial Results

Net losses narrowed Recent sale of Company's Share in Collaboration and Equity Issuance to Pfizer Yielding a Total of $46 Million to Help Aggressively Push all Three Product...
October 19, 2015 07:30 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Reports Positive Long Term Data on PRX-102 for Fabry Disease

Significantly Improved PK Characteristics Result in: Higher Active Enzyme Quantities, Induced Immune Tolerance Meaningful Clinical Benefit Demonstrated Across All Key Disease Parameters...
October 13, 2015 07:30 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Sells Its Share in Collaboration Agreement for ELELYSO and a 6% Equity Stake in Protalix to Pfizer for a Total of $46 Million

Protalix to Use Funds to Aggressively Push Its Clinical Pipeline Forward and Execute Its New Strategy of Developing Clinically Superior Biologics Protalix Receives All Rights to ELELYSO in...
October 05, 2015 08:00 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics to Explore Non Alcoholic Steato Hepatitis (NASH) as an Indication for Its PRX 106 Oral Anti TNF

CARMIEL, Israel, Oct. 5, 2015 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today pre-clinical data for PRX-106 in Non-alcoholic Steatohepatits (NASH), a...
September 09, 2015 07:00 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Reports Positive Phase I/II Interim Clinical Data on the 1mg/kg Cohort of PRX-102 for Fabry Disease

Positive efficacy data across all disease parameters Positive safety data with low level of antibody formation End of Phase II meeting with FDA scheduled before year end CARMIEL, Israel, Sept....
August 10, 2015 16:30 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Reports Second Quarter 2015 Financial Results

CARMIEL, Israel, Aug. 10, 2015 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), today reported financial results for the second quarter of 2015. "We recently reported...